IBCL-482: Fixed-Duration Subcutaneous Mosunetuzumab (Mosun SC) Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome (CRS), and Non-Inferior Exposure Compared With Intravenous Administration in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Primary Analysis of a Pivotal Phase 2 Study
Year: 2025
Type: article
Authors: Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung-Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Antonia Kwan, Elicia Penuel, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde
Institutions: Washington University in St. Louis, Alvin J. Siteman Cancer Center, University of British Columbia, Jewish General Hospital, Royal Adelaide Hospital, Princess Margaret Cancer Centre, Abramson Cancer Center, University of Pennsylvania, Seoul National University Hospital, Royal North Shore Hospital, Johannes Gutenberg University Mainz, University Medical Center of the Johannes Gutenberg University Mainz, Ludwig-Maximilians-Universität München, Instituto de Investigación Biomédica de Salamanca, Genentech, City Of Hope National Medical Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4413774148